Loading…
Loading…
Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. [url="]announced[/url] that updated data, including overall survival (OS), from
Healthcare Realty Trust (HR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AstraZeneca's ETCAMAHÂ (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib) has been appro
Healthcare Realty Trust (HR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Healthcare Realty Trust (HR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Healthcare Realty Trust NYSE: HR reported second-quarter results marked by higher occupancy, leasing activity, same-store net operating income growth and an increase to its full-year funds-from-operations outlook. Management said the company's performance continues to run ahead of objectives outlined in its strategic plan one year ago.
Healthcare Realty Trust Incorporated (HR) Q2 2026 Earnings Call Transcript
Healthcare Realty Trust (HR) came out with quarterly funds from operations (FFO) of $0.41 per share, beating the Zacks Consensus Estimate of $0.4 per share. This compares to FFO of $0.41 per share a year ago.